Advances in biological agents in the treatment of inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic and progressive disease which is currently hard to cure. Traditional treatments, such as aminosalicylates, steroids and immunosuppressants, can only alleviate symptoms, but can’t prevent potential inflammation or change the disease progress. The applicat...
Saved in:
| Main Authors: | Na LI, Mei YE |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of New Medicine
2022-08-01
|
| Series: | Yixue xinzhi zazhi |
| Subjects: | |
| Online Access: | https://yxxz.whuznhmedj.com/storage/attach/2208/VO4xeZPbBch7s5ayeMl0E67uHzjTH7n8Zocmy2z5.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative Effectiveness of Dual Biologic Therapy and Biologic Small‐Molecule Therapy for Refractory Inflammatory Bowel Disease: A Retrospective Single‐Center Study
by: Fan Yin, et al.
Published: (2025-03-01) -
Mapping the Evolution of IBD Treatment: A Bibliometric Study on Biologics and Small Molecules
by: Huibo Li, et al.
Published: (2025-02-01) -
Cutaneous side effects caused by treatment for inflammatory bowel disease
by: Dino Tarabar, et al.
Published: (2016-01-01) -
A Review of the Current State of Off‐Label Therapies for Pediatric Inflammatory Bowel Disease
by: Yassin EL‐Najjar, et al.
Published: (2025-06-01) -
Adherence to treatment with adalimumab, golimumab and ustekinumab in patients with inflammatory bowel disease
by: María Calvo-Arbeloa, et al.
Published: (2020-03-01)